drugset / Trial / NCT04843787
SLV213 Treatment in Ambulatory COVID-19 Patients
RandomizedSequentialQuadruple-blindTreatment
Summary
This Phase 2a trial recruits adult ambulatory patients who have been determined to be COVID-19 positive. The study drug SLV213 will be administered to examine its safety, tolerability and provide assessment of its effect on clinical symptoms of COVID-19. Blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) analysis.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2024-06-01
- Completion
- 2024-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | K777 | Small molecule | 200 mg | Oral |
| Subject | K777 | Small molecule | 400 mg | Oral |
| Subject | K777 | Small molecule | 800 mg | Oral |